Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs-a multicenter, double-blind, parallel-group trial

Shinichi Kawai, Tsutomu Takeuchi, Kazuhiko Yamamoto, Yoshiya Tanaka, Nobuyuki Miyasaka

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

In this trial, we investigated the safety and efficacy of tacrolimus used in addition to standard antirheumatic drugs in patients with rheumatoid arthritis. Tacrolimus 3 mg or placebo was orally administered once daily for 52 weeks in a double-blind manner to patients with early active rheumatoid arthritis receiving other disease- modifying antirheumatic drugs (DMARDs). A total of 123 patients were randomized to the tacrolimus group (61 patients) and to the placebo group (62 patients). In the tacrolimus group, 70.5% achieved a clinical response according to American College of Rheumatology (ACR) 20 criteria, whereas 45.2% in the placebo group did so (P = 0.005). The tacrolimus group also showed significant improvement in terms of the European League Against Rheumatism (EULAR) response criteria of 'good or moderate' versus the placebo group (86.9 vs. 56.5%, respectively). Likewise, significantly more patients in the tacrolimus group versus the placebo group achieved remission of the Disease Activity Score in 28 joints (DAS28) (45 vs. 21%). The mean changes in the Total Sharp Score and erosion score were lower in the tacrolimus group, but the differences between the two groups were not significant. There was no significant difference between the two groups in the incidence of adverse events. Based on these results, we can conclude that the additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to other DMARD treatments is useful, and this could become one of the treatment options for these rheumatoid arthritis patients.

Original languageEnglish
Pages (from-to)458-468
Number of pages11
JournalModern Rheumatology
Volume21
Issue number5
DOIs
Publication statusPublished - 2011 Oct

Fingerprint

Antirheumatic Agents
Tacrolimus
Rheumatoid Arthritis
Safety
Placebos
Joints
Incidence
Therapeutics

Keywords

  • DMARD
  • Randomized controlled trial
  • Rheumatoid arthritis
  • Tacrolimus

ASJC Scopus subject areas

  • Rheumatology

Cite this

Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs-a multicenter, double-blind, parallel-group trial. / Kawai, Shinichi; Takeuchi, Tsutomu; Yamamoto, Kazuhiko; Tanaka, Yoshiya; Miyasaka, Nobuyuki.

In: Modern Rheumatology, Vol. 21, No. 5, 10.2011, p. 458-468.

Research output: Contribution to journalArticle

@article{2a32f69aa13e422eaf516b75852f6243,
title = "Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs-a multicenter, double-blind, parallel-group trial",
abstract = "In this trial, we investigated the safety and efficacy of tacrolimus used in addition to standard antirheumatic drugs in patients with rheumatoid arthritis. Tacrolimus 3 mg or placebo was orally administered once daily for 52 weeks in a double-blind manner to patients with early active rheumatoid arthritis receiving other disease- modifying antirheumatic drugs (DMARDs). A total of 123 patients were randomized to the tacrolimus group (61 patients) and to the placebo group (62 patients). In the tacrolimus group, 70.5{\%} achieved a clinical response according to American College of Rheumatology (ACR) 20 criteria, whereas 45.2{\%} in the placebo group did so (P = 0.005). The tacrolimus group also showed significant improvement in terms of the European League Against Rheumatism (EULAR) response criteria of 'good or moderate' versus the placebo group (86.9 vs. 56.5{\%}, respectively). Likewise, significantly more patients in the tacrolimus group versus the placebo group achieved remission of the Disease Activity Score in 28 joints (DAS28) (45 vs. 21{\%}). The mean changes in the Total Sharp Score and erosion score were lower in the tacrolimus group, but the differences between the two groups were not significant. There was no significant difference between the two groups in the incidence of adverse events. Based on these results, we can conclude that the additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to other DMARD treatments is useful, and this could become one of the treatment options for these rheumatoid arthritis patients.",
keywords = "DMARD, Randomized controlled trial, Rheumatoid arthritis, Tacrolimus",
author = "Shinichi Kawai and Tsutomu Takeuchi and Kazuhiko Yamamoto and Yoshiya Tanaka and Nobuyuki Miyasaka",
year = "2011",
month = "10",
doi = "10.1007/s10165-011-0425-8",
language = "English",
volume = "21",
pages = "458--468",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "5",

}

TY - JOUR

T1 - Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs-a multicenter, double-blind, parallel-group trial

AU - Kawai, Shinichi

AU - Takeuchi, Tsutomu

AU - Yamamoto, Kazuhiko

AU - Tanaka, Yoshiya

AU - Miyasaka, Nobuyuki

PY - 2011/10

Y1 - 2011/10

N2 - In this trial, we investigated the safety and efficacy of tacrolimus used in addition to standard antirheumatic drugs in patients with rheumatoid arthritis. Tacrolimus 3 mg or placebo was orally administered once daily for 52 weeks in a double-blind manner to patients with early active rheumatoid arthritis receiving other disease- modifying antirheumatic drugs (DMARDs). A total of 123 patients were randomized to the tacrolimus group (61 patients) and to the placebo group (62 patients). In the tacrolimus group, 70.5% achieved a clinical response according to American College of Rheumatology (ACR) 20 criteria, whereas 45.2% in the placebo group did so (P = 0.005). The tacrolimus group also showed significant improvement in terms of the European League Against Rheumatism (EULAR) response criteria of 'good or moderate' versus the placebo group (86.9 vs. 56.5%, respectively). Likewise, significantly more patients in the tacrolimus group versus the placebo group achieved remission of the Disease Activity Score in 28 joints (DAS28) (45 vs. 21%). The mean changes in the Total Sharp Score and erosion score were lower in the tacrolimus group, but the differences between the two groups were not significant. There was no significant difference between the two groups in the incidence of adverse events. Based on these results, we can conclude that the additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to other DMARD treatments is useful, and this could become one of the treatment options for these rheumatoid arthritis patients.

AB - In this trial, we investigated the safety and efficacy of tacrolimus used in addition to standard antirheumatic drugs in patients with rheumatoid arthritis. Tacrolimus 3 mg or placebo was orally administered once daily for 52 weeks in a double-blind manner to patients with early active rheumatoid arthritis receiving other disease- modifying antirheumatic drugs (DMARDs). A total of 123 patients were randomized to the tacrolimus group (61 patients) and to the placebo group (62 patients). In the tacrolimus group, 70.5% achieved a clinical response according to American College of Rheumatology (ACR) 20 criteria, whereas 45.2% in the placebo group did so (P = 0.005). The tacrolimus group also showed significant improvement in terms of the European League Against Rheumatism (EULAR) response criteria of 'good or moderate' versus the placebo group (86.9 vs. 56.5%, respectively). Likewise, significantly more patients in the tacrolimus group versus the placebo group achieved remission of the Disease Activity Score in 28 joints (DAS28) (45 vs. 21%). The mean changes in the Total Sharp Score and erosion score were lower in the tacrolimus group, but the differences between the two groups were not significant. There was no significant difference between the two groups in the incidence of adverse events. Based on these results, we can conclude that the additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to other DMARD treatments is useful, and this could become one of the treatment options for these rheumatoid arthritis patients.

KW - DMARD

KW - Randomized controlled trial

KW - Rheumatoid arthritis

KW - Tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=84855711892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855711892&partnerID=8YFLogxK

U2 - 10.1007/s10165-011-0425-8

DO - 10.1007/s10165-011-0425-8

M3 - Article

VL - 21

SP - 458

EP - 468

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 5

ER -